Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
about
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectivesCurrent management of chronic myeloid leukemia with tyrosine kinase inhibitors.Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluationHistopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers.Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.
P2860
Q30242015-355B1387-983A-4B24-AB35-3D2527A938B3Q36386428-CA028E90-78E6-42DC-A0AC-2EBDE16E1F7FQ37426573-10C5D1F3-75AC-49EB-8D26-9B119C8B1369Q37911537-F91D83D8-A663-4F97-B538-54DD86A665EFQ38033115-7ECB01FE-421D-4022-8F6E-4D089EC8080BQ38066199-A3D2C60E-B907-4FD7-B4D6-29B6E66930E9Q38132855-9D912962-DFAE-4364-B4BA-F4B1E3C6F7F1Q38148243-0FF73ACC-971D-4473-B8ED-5B7D70B7AAE5Q38167808-47303935-DF3F-4C35-82F2-F7A576B7244DQ38253243-26C6C738-408A-4DB9-8F5D-92AB3145E0F4Q40007199-0620D8A9-6C6C-4041-A058-013152DDA037Q50916805-E8F70CFF-A549-4438-AECF-EA9C3B5F0E6FQ52820899-2CB6AAF8-343A-475A-9312-8ED573AC3A36
P2860
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Second-generation BCR-ABL inhi ...... oid leukemia in chronic phase.
@en
Second-generation BCR-ABL inhi ...... oid leukemia in chronic phase.
@nl
type
label
Second-generation BCR-ABL inhi ...... oid leukemia in chronic phase.
@en
Second-generation BCR-ABL inhi ...... oid leukemia in chronic phase.
@nl
prefLabel
Second-generation BCR-ABL inhi ...... oid leukemia in chronic phase.
@en
Second-generation BCR-ABL inhi ...... oid leukemia in chronic phase.
@nl
P50
P1476
Second-generation BCR-ABL inhi ...... oid leukemia in chronic phase.
@en
P304
P356
10.1016/J.CRITREVONC.2011.04.002
P577
2011-05-11T00:00:00Z